2m 2m 2m 2m 2m 2m 2m
ARRIVENT BIO (AVBP)
NASDAQ
$33.75+$0.005 (+0.01%)
Price as of Jun 23, 2026 4:10 PM EDT- $1.5BMarket Cap
- 43.42%1-Year Change
- BiotechnologyIndustry
ARRIVENT BIO (AVBP)
$33.75+$0.005 (+0.01%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -153.4M +94.11% | -79.0M N/A | |
Depreciation and Amortization Expense | -3.0M N/A | N/A N/A | |
Total Operating Expenses | 177.5M +88.25% | 94.3M N/A | |
Operating Profit | -177.5M +88.25% | -94.3M N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | |
Income before Taxes | -177.5M +88.25% | -94.3M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -166.3M +106.62% | -80.5M N/A | |
Net Income from Continuing Operations Applicable to Common | -166.3M +106.62% | -80.5M N/A | |
Basic EPS and Net Income | -4.32 +68.75% | -2.56 N/A | |
Diluted EPS and Net Income | -4.32 +68.75% | -2.56 N/A | |
Basic Weighted Average Shares | 38.5M +22.22% | 31.5M N/A | |
Diluted Weighted Average Shares | 38.5M +22.22% | 31.5M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 45.5M -38.70% | 74.3M N/A | |
Short-Term Investments | 267.3M +84.88% | 144.6M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 312.8M +42.93% | 218.9M N/A | |
Total Current Assets | 332.9M +46.66% | 227.0M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 190,000 +50.79% | 126,000 N/A | |
Total Assets | 333.2M +21.18% | 274.9M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 25.9M +50.20% | 17.3M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 14,000 0.00% | 14,000 N/A | |
Total Liabilities | 25.9M +50.08% | 17.3M N/A | |
Retained Earnings | -404.6M +69.78% | -238.3M N/A | |
Total Stockholders Equity | 307.2M +19.24% | 257.7M N/A | |
Total Shares Outstanding | 42.5M +25.95% | 33.7M N/A | |
Cash Flow | |||
Cash from Operating Activities | -160.6M +128.72% | -70.2M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -71.2M -62.99% | -192.5M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 203.1M +8.83% | 186.6M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -54.70% N/A | N/A N/A | |
Return on Equity | -58.88% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 12.83 N/A | N/A N/A | |
Cash Ratio | 1.76 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow